Up to one year of treatment with Takhzyro (lanadelumab) significantly reduced rates of swelling attacks and improved quality of life for children with hereditary angioedema (HAE) ages 2 through 11, according to results from the Phase 3 SPRING clinical trial. Results from the trial helped support the U.S.
New treatments for hereditary angioedema (HAE) have been life-changing for people in the U.K., but more and better efforts are needed to educate emergency workers on providing care, according to a new study. The survey study found that HAE patients in Great Britain still frequently have upsetting experiences when…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the approval of Takhzyro (lanadelumab) for the routine prevention of hereditary angioedema (HAE) attacks in children starting at age 2. Based on a positive opinion from the CHMP, the European…
A 46-year-old man developed delayed angioedema following surgery — with his tongue swelling significantly four hours later — that likely was triggered by the use of an ACE or angiotensin-converting enzyme inhibitor to treat his high blood pressure, according to a new case report. Due to rapid evaluation by…
The Institut national d’excellence en santé et services sociaux (INESSS) has recommended that BioCryst Pharmaceuticals’ Orladeyo (berotralstat) be reimbursed by public health plans for eligible adults and adolescents 12 and older with hereditary angioedema (HAE) in the Canadian province of Québec. A similar recommendation was made earlier…
Women with hereditary angioedema (HAE) see an increase in the number and severity of disease attacks during pregnancy and while breastfeeding, according to a study in Turkey. A normal vaginal delivery without anesthesia was associated with a lower attack rate, leading researchers to argue that in the absence of “special…
People who develop angioedema due to common high blood pressure medications known as angiotensin-converting enzyme (ACE) inhibitors may be at an increased risk of a cardiovascular event in the few months after discontinuing treatment, a study has found. While it’s not clear if switching to an alternative treatment may…
Takhzyro (lanadelumab) may be better than Cinryze at preventing swelling episodes in hereditary angioedema (HAE), according to a study based on data from Phase 3 clinical trials. The study, “Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study,” was published…
A significant proportion of people diagnosed with drug-induced angioedema due to using certain blood pressure medications — namely angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin 2 receptor blockers (ARBs) — were misdiagnosed, according to a recent report from France. These patients, who continued to experience recurrent angioedema attacks more than…
Treatment with Orladeyo (berotralstat) effectively prevented swelling and improved life quality for three people with hereditary angioedema (HAE) with no known disease-causing mutations. “Our results provide the first evidence that [Orladeyo] can be an effective therapy in patients with HAE [who do not have any known mutations],” scientists…
Get regular updates to your inbox.